In this issue of Insights, we summarize a recent discussion held with a number of pharmaceutical companies on US health policy, potential priorities for the Trump administration, and yes, pricing. Tim Wilsdon, an expert in international policy issues affecting the development and commercialization of medicines, led the discussion.
To read more, click the link below.
An evidence-based framework to determine funding requirements for NCCPs
The report finds that NCCPs rarely specify the funds that need to be committed or the spending that occurs in practice. When evidence of funding impact is...